Cargando…

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5

BNT162b2-vaccinated individuals after Omicron BA.1 breakthrough infection have strong serum neutralizing activity against Omicron BA.1, BA.2, and previous SARS-CoV-2 variants of concern (VOCs), yet less against the highly contagious Omicron sublineages BA.4 and BA.5 that have displaced previous vari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muik, Alexander, Lui, Bonny Gaby, Bacher, Maren, Wallisch, Ann-Kathrin, Toker, Aras, Finlayson, Andrew, Krüger, Kimberly, Ozhelvaci, Orkun, Grikscheit, Katharina, Hoehl, Sebastian, Ciesek, Sandra, Türeci, Özlem, Sahin, Ugur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2022
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529054/ https://www.ncbi.nlm.nih.gov/pubmed/36125366 http://dx.doi.org/10.1126/sciimmunol.ade2283

Ejemplares similares

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
por: Muik, Alexander, et al.
Publicado: (2022)

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
por: Quandt, Jasmin, et al.
Publicado: (2022)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
por: Torres, Carolina, et al.
Publicado: (2023)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
por: Wang, Qian, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
por: Huo, Jiandong, et al.
Publicado: (2022)

Estimating the serial intervals of SARS‐CoV‐2 Omicron BA.4, BA.5, and BA.2.12.1 variants in Hong Kong
por: Guo, Zihao, et al.
Publicado: (2023)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
por: Wilhelm, Alexander, et al.
Publicado: (2022)

Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection
por: Cheng, Samuel SM, et al.
Publicado: (2022)

Structural Characteristics of Heparin Binding to SARS-CoV-2 Spike Protein RBD of Omicron Sub-Lineages BA.2.12.1, BA.4 and BA.5
por: Shi, Deling, et al.
Publicado: (2022)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 — China, 2020–2021
por: Chen, Xinhua, et al.
Publicado: (2023)

COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period
por: Wang, Lindsey, et al.
Publicado: (2022)

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5
por: Bormann, Maren, et al.
Publicado: (2023)

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era
por: Sridhara, Srilekha, et al.
Publicado: (2023)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Impact of mutations defining SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 on Spike function and neutralization
por: Pastorio, Chiara, et al.
Publicado: (2023)

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022
por: Atari, Nofar, et al.
Publicado: (2022)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1
por: Rodino, Kyle G., et al.
Publicado: (2022)

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
por: Ai, Jingwen, et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Serum Neutralization of Omicron BA.5, BA.2 and BA.1 in Triple Vaccinated Kidney Transplant Recipients
por: Pedersen, Rune M., et al.
Publicado: (2022)

Early Detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German Wastewater
por: Wilhelm, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_12tens3mipbb5fga9i009u3iap